3
Announcements
Trials
Browse
Landscape
Status
Available
2
No longer available
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
93
Observational
4
Expanded_access
3
Sponsor
Cancer Type
Myeloid
3
Lymphoid
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
32
Multiple Myeloma
26
Neoplasms
25
Recurrence
23
Melanoma
19
Leukemia, Myeloid, Acute
16
Breast Neoplasms
15
Prostatic Neoplasms
12
Pancreatic Neoplasms
11
Glioblastoma
11
Sarcoma
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lung Neoplasms
9
Ovarian Neoplasms
8
Lymphoma
8
Glioma
8
Colorectal Neoplasms
8
Small Cell Lung Carcinoma
7
Lymphoma, Large B-Cell, Diffuse
7
Carcinoma, Renal Cell
7
Lymphoma, Non-Hodgkin
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Gastrointestinal Stromal Tumors
6
Cholangiocarcinoma
6
Triple Negative Breast Neoplasms
5
Stomach Neoplasms
5
Neoplasm Metastasis
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Thyroid Neoplasms
4
Lymphoma, Mantle-Cell
4
Interventions
venetoclax
1
selinexor
1
ruxolitinib
1
navitoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Expanded_access
×
Primary Myelofibrosis
×
Clear all
NCT07215832
2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT04745637
2025-11-18
Managed Access Programs for INC424, Ruxolitinib
Novartis
Available
NCT03592576
2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available